Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Cash from Operations of 32956000.0 for Q1 2026, down 0.98% year-over-year from 33282337.42 in Q1 2025, and down 6.52% quarter-over-quarter from 30940000.0 in Q4 2025.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 32956000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 0.98% year-over-year to 32956000.0; the TTM figure through Mar 2026 stood at 125567000.0 (up 17.13% YoY), while the FY2025 annual figure was 125247000.0, up 26.7% from the prior year.
- Cash from Operations for Q1 2026 stood at 32956000.0, down from 30940000.0 in the prior quarter.
- The five-year high for Cash from Operations was 26963000.0 in Q3 2025, with the low at 79275000.0 in Q2 2023.
- The 5-year median for Cash from Operations is 38665000.0 (2023), against an average of 41213882.35.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 84.24% in 2023, then surged 55.67% in 2024.
- Zentalis Pharmaceuticals' Cash from Operations stood at 37329000.0 in 2022, then declined by 8.76% to 40599000.0 in 2023, then advanced by 2.21% to 39702000.0 in 2024, then rose by 22.07% to 30940000.0 in 2025, then retreated by 6.52% to 32956000.0 in 2026.
- Business Quant data shows ZNTL's Cash from Operations at 32956000.0 in Q1 2026, 30940000.0 in Q4 2025, and 26963000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | -37.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.24 Mn |
| Mar 31, 2026 | -32.96 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Jun 30, 2024 | -35.14 Mn |
| Mar 31, 2024 | -51.97 Mn |
| Dec 31, 2023 | -40.60 Mn |
| Sep 30, 2023 | -38.67 Mn |
| Jun 30, 2023 | -79.28 Mn |
| Mar 31, 2023 | -49.28 Mn |
| Dec 31, 2022 | -37.33 Mn |
| Sep 30, 2022 | -33.20 Mn |
| Jun 30, 2022 | -43.03 Mn |
| Mar 31, 2022 | -50.20 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Sep 30, 2021 | -33.49 Mn |